A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
出版年份 2016 全文链接
标题
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
作者
关键词
Copanlisib, PI3K inhibitor, Japanese, Solid tumors
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 79, Issue 1, Pages 89-98
出版商
Springer Nature
发表日期
2016-12-03
DOI
10.1007/s00280-016-3198-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
- (2015) J. R. Brown et al. CLINICAL CANCER RESEARCH
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
- (2015) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
- (2014) N. A. O'Brien et al. CLINICAL CANCER RESEARCH
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
- (2014) Carolyn D. Britten et al. INVESTIGATIONAL NEW DRUGS
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
- (2012) Naifa L. Busaidy et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Contribution of Insulin and Akt1 Signaling to Endothelial Nitric Oxide Synthase in the Regulation of Endothelial Function and Blood Pressure
- (2009) J. David Symons et al. CIRCULATION RESEARCH
- Targeting the PI3K signaling pathway in cancer
- (2009) Kwok-Kin Wong et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways
- (2009) Mark R Lackner EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
- (2008) M.-C. Crouthamel et al. CLINICAL CANCER RESEARCH
- Akt as a therapeutic target in cancer
- (2008) Linda S Steelman et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now